Plasma Protease C1-inhibitor Treatment is used in the management of various inflammatory and autoimmune diseases. It prevents the inappropriate activation of plasma cascade pathways.
Market key trends:
Increasing research and development activities in the field of plasma therapies have accelerated the growth of the Plasma Protease C1-inhibitor Treatment Market. Ongoing clinical trials are exploring the applications of plasma therapies in the treatment of various rare and chronic diseases such as hereditary angioedema (HAE) and ischemia reperfusion injury. According to recent data, over 50 clinical trials are currently investigating the role of plasma therapies for various indications. These ongoing R&D initiatives are expected to drive market growth by expanding approved therapeutic applications of plasma protease C1-inhibitor during the forecast period.
Segment Analysis
The global plasma protease C1-inhibitor treatment market is dominated by the hereditary angioedema (HAE) sub segment. This sub segment holds a major market share owing to the increasing prevalence of hereditary angioedema globally. HAE is caused due to a deficiency of C1-inhibitor protein which regulates some components of the complement system and contact system in blood. The treatments available for HAE include plasma derived C1-inhibitor treatment which provides adequate management of HAE by preventing angioedema attacks.
Key Takeaways
The Global Plasma Protease C1-inhibitor Treatment Market Demand is expected to witness high growth over the forecast period owing to the rising cases of hereditary angioedema worldwide. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024-2031.
Regional analysis: North America currently dominates the global market and is expected to maintain its dominance during the forecast period. This is attributed to the growing awareness about plasma derived C1-inhibitor treatment in the region. However, Asia Pacific is anticipated to witness the highest growth rate owing to the increasing healthcare expenditure and improving access to plasma protease C1-inhibitor treatment in emerging countries of the region.
Key players: Key players operating in the plasma protease C1-inhibitor treatment market are R&D, Koninklijke Philips N.V., and Panasonic Corporation. These players are focusing on new product launches and strategic collaborations to strengthen their market position. For instance, in 2021, R&D received approval for its plasma protease C1-inhibitor treatment drug for adults and adolescents with hereditary angioedema in Europe.
Explore more information on this topic, Please visit -
Explore more trending article related this topic -
Comments
0 comment